化合物AZD8055 T1859
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
TargetMol | 生产商 | 美国 | 现货 |
性能特点
生化试剂,可用于动物细胞实验
规格 | CAS号 | 价格 | 操作 |
---|---|---|---|
1 mg | 1009298-09-2 | ¥172.00 | 询底价 |
100 mg | 1009298-09-2 | ¥2,470.00 | 询底价 |
500 mg | 1009298-09-2 | ¥6,350.00 | 询底价 |
1 mL | 1009298-09-2 | ¥418.00 | 询底价 |
200 mg | 1009298-09-2 | ¥3,950.00 | 询底价 |
50 mg | 1009298-09-2 | ¥1,560.00 | 询底价 |
10 mg | 1009298-09-2 | ¥622.00 | 询底价 |
25 mg | 1009298-09-2 | ¥987.00 | 询底价 |
5 mg | 1009298-09-2 | ¥378.00 | 询底价 |
Product Introduction
Bioactivity
英文名: AZD-8055
描述: AZD-8055 是一种选择性、具有口服活性和 ATP 竞争性的 mTOR 抑制剂,IC50为 0.8 nM。AZD-8055 抑制 mTORC1和 mTORC2。
细胞实验: For growth inhibition and acridine staining, cells were exposed to increasing concentrations of AZD8055 for 72 to 96 h and stained for cell nuclei (0.03 mg/mL Hoechst 33342) and acidic vesicles (1 μg/mL acridine orange). Images were captured at 450 and 536 nm on an ArrayScan II platform, and the percentage of acidic vesicles and the number of cells were quantified. For LC3 assessment, cells were exposed to e64d/pepstatin (10 μg/mL) for 30 to 90 min before incubation with AZD8055. Cells were lysed on ice and analyzed by immunoblotting [1].
激酶实验: The activity of mTOR was assayed using the recombinant mTOR technique described above. For inhibition experiments, AZD8055 was added to the reaction mixture and preincubated for 10 min before addition of ATP. Inhibition was performed at 1 to 3,000 nmol/L of AZD8055 in varying concentrations of ATP (40–200 μmol/L) [1].
动物实验: Tumor cells (10^6 for U87-MG, 5 × 10^6 for A549) were injected s.c. in a volume of 0.1 mL, and mice were randomized into control and treatment groups when tumor size reached 0.2 cm^3. AZD8055 was formulated in 30% (w/v) captisol (pH 3.0). The control group received the vehicle only. Tumor volumes (measured by caliper), animal body weight, and tumor condition were recorded twice weekly for the duration of the study. The tumor volume was calculated (taking length to be the longest diameter across the tumor and width to be the corresponding perpendicular diameter) using the following formula: (length × width) × √(length × width) × (π/6) [1].
体外活性: AZD8055 inhibits the phosphorylation of mTORC1 substrates p70S6K and 4E-BP1 as well as phosphorylation of the mTORC2 substrate AKT and downstream proteins. The rapamycin-resistant T37/46 phosphorylation sites on 4E-BP1 were fully inhibited by AZD8055, resulting in significant inhibition of cap-dependent translation. In vitro, AZD8055 potently inhibits proliferation and induces autophagy in H838 and A549 cells [1]. In vitro, the median relative IC50 for AZD8055 against the PPTP cell lines was 24.7?nM. Relative I/O values >0% were observed in 8 cell lines and 15 cell lines showed Relative I/O values ranging from -4.7 to -92.2% [2].
体内活性: In vivo, AZD8055 induces a dose-dependent pharmacodynamic effect on phosphorylated S6 and phosphorylated AKT at plasma concentrations leading to tumor growth inhibition [1]. AZD8055 administration could significantly decrease the IL-1β and TNF-α concentrations. Rats subjected to SAH + vehicle group demonstrated histological evidence of apoptosis compared with the sham group. The group treated with AZD8055 demonstrated a significant decrease in apoptosis ratio in the rat brain sample. In addition, in SAH group, the number of fluoro-jade B-positive cells clearly increased compared with the sham group. And the number of fluoro-jade B-positive cells decreased significantly in the SAH + rapamycin group and SAH + AZD8055 group [3].
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: Ethanol : 3 mg/mL (6.44 mM)
H2O : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 45 mg/mL (96.66 mM)
关键字: AZD8055 | inhibit | AZD-8055 | Apoptosis | mTOR | Mammalian target of Rapamycin | Inhibitor | Autophagy | AZD 8055
相关产品: Taurodeoxycholic acid sodium hydrate | Avadomide | Mevastatin | Grape Seed Extract | Fludarabine | LW6 | Onatasertib | Escin | Formononetin | ARS-853
相关库: Anti-Aging Compound Library | Drug Repurposing Compound Library | Anti-Cancer Drug Library | Anti-Lung Cancer Compound Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Kinase Inhibitor Library | Anti-Cancer Active Compound Library | Highly Selective Inhibitor Library | Reprogramming Compound Library
化合物AZD8055 T1859信息由TargetMol中国为您提供,如您想了解更多关于化合物AZD8055 T1859报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途